Richard Gallegos

Statistics

Publications

Citations

400

H-Index

Active since

1996

Affiliations

Millennium Engineering and Integration (United States)(Current)

Concert Pharmaceuticals (United States)

Richard Gallegos is an author at Millennium Engineering and Integration (United States) specializing in drug discovery, quantitative pharmacology, and immunology.

ORCID

Top concepts

MedicineImmunologyPharmacologyImmunotherapyDrug DiscoveryPharmacotherapyDrug DevelopmentRadiation OncologyMedicinal ChemistryClinical Pharmacology

Publications per year

1996–2015

Publications

WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135.

Casimir A. Fornal, Richard Gallegos, Sigrid C. Veasey et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 163 citations

Comparison of Intrinsic Clearance in Liver Microsomes and Hepatocytes from Rats and Humans: Evaluation of Free Fraction and Uptake in Hepatocytes

Chuang Lu, Ping Li, Richard Gallegos et al. · Drug Metabolism and Disposition · 2006 · 141 citations

Altering Metabolic Profiles of Drugs by Precision Deuteration: Reducing Mechanism-Based Inhibition of CYP2D6 by Paroxetine

Vinita Uttamsingh, Richard Gallegos, Julie F. Liu et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 55 citations

INVESTIGATION OF DRUG-DRUG INTERACTION POTENTIAL OF BORTEZOMIB IN VIVO IN FEMALE SPRAGUE-DAWLEY RATS AND IN VITRO IN HUMAN LIVER MICROSOMES

Chuang Lu, Richard Gallegos, Ping Li et al. · Drug Metabolism and Disposition · 2006 · 30 citations

Abstract 3357: CTP-221, a deuterated S-enantiomer of lenalidomide, is greatly stabilized to epimerization and results in a more desirable pharmacokinetic profile than racemic lenalidomide.

Vinita Uttamsingh, Richard Gallegos, Changfu Cheng et al. · Cancer Research · 2013 · 11 citations

Immunology, Pharmacotherapy, Immunotherapeutics +18

1–5 of 5